Intervention of interest: Mepolizumab (Nucala®, GlaxoSmithKline plc.) An estimated 22 million Americans have asthma, which causes the airways of the lungs to narrow or become blocked, making it hard to breathe. Among both young and old, asthma can have a significant impact on health and limit the ability to pursue many activities. For questions, contact […]
Interventions of Interest Dupilumab (Dupixent®, Sanofi/Regeneron) Omalizumab (Xolair®, Genentech/Novartis) Mepolizumab (Nucala®, GlaxoSmithKline) Reslizumab (Cinqair®, Teva) Benralizumab (Fasenra™, AstraZeneca) An estimated 22 million Americans have asthma, which causes the airways of the lungs to narrow or become blocked, making it hard to breathe. Among both young and old, asthma can have a significant impact on health […]
Interventions of Interest: crisaborole (Eucrisa®, Pfizer, Inc.) dupilumab (Dupixent®, Sanofi and Regeneron, Inc.) Atopic dermatitis (eczema) is a chronic/chronically-relapsing skin condition characterized by itching and dry skin. Atopic dermatitis is common. It affects 5-20% of children worldwide, and approximately 11% of children in the US. It is also estimated to affect around 3-7% of adults […]
Interventions of interest: Antiarrhythmic drugs (amiodarone, dronedarone) Catheter ablation Surgical ablation Atrial fibrillation (AF) is the most common cardiac arrhythmia in the US population. AF occurs when rapid, disorganized electrical signals cause the atria (the two upper chambers of the heart) to “fibrillate”, or contract quickly and irregularly. This in turn causes some blood to […]
Interventions of interest: Parent behavior training School-based interventions Stimulants Non-stimulants Diagnoses of Attention Deficit Hyperactivity Disorder (ADHD) have risen in recent years, and ADHD is now regarded to be a common condition among children in the United States. While reported prevalence ranges widely between 6-16% depending on location and measurement technique, it has been estimated […]
Intervention of interest: Programs to integrate behavioral health into the primary care setting Providers in the US health care system often assess and treat patients with physical health conditions and behavioral health conditions (e.g., mental health and substance use disorders) in siloes, yet physical and behavioral health are inextricably linked. Up to 70% of physician […]
Intervention of Interest LentiGlobin (Zynteglo®, Bluebird Bio) ICER planned to assess the comparative clinical effectiveness and value of LentiGlobin (Bluebird Bio) for the treatment of beta thalassemia. LentiGlobin is an investigational gene therapy currently marketed in Europe under the brand name Zynteglo®. On December 5, 2019, ICER launched our assessment of LentiGlobin, originally intending to conclude the […]
This report examines the comparative effectiveness and value of screening options for women with dense breast tissue, including hand-held and automated breast ultrasound, digital breast tomosynthesis (DBT), and magnetic resonance imaging (MRI). The CTAF Panel voted that the evidence supports supplemental screening of women at high risk for breast cancer, and that screening with MRI, among commonly used screening […]
Treatments of Interest: icosapent ethyl (Vascepa®, Amarin Pharma) rivaroxaban (Xarelto®, Janssen Pharmaceuticals) Cardiovascular disease (CVD) is a set of conditions that result primarily from the build-up of plaque in the blood vessels. Depending on where there is build-up, patients can have chest pain (“angina”), muscle pain with walking (“claudication”) and an increased risk of heart […]
Interventions of interest: Hand-held and automated breast ultrasound Digital breast tomosynthesis (DBT) Magnetic resonance imaging (MRI) Following a negative mammogram, many women with dense breast tissue face a decision: whether to receive additional screening, and if so, what modality to use. Many mammography facilities are now informing women with dense breasts about the potential for […]